Analyzing...
Loading company...
Produces Ayurvedic medicines and herbal products. Revenue comes from B2B and retail sales. Focuses on natural sourcing, quality, and regulatory compliance. Operates manufacturing and retail distribution model.
Excluded by gate
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Equipment & Devices.”
₹107 Cr revenue.
COGS 17.7%, employees 17.0%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.5%▲ | 8.6% |
| ROCE | 12.5%▼ | 12.6% |
| Net Margin | 8.2%▼ | 8.2% |
| EBITDA Margin | 16.3%▲ | 15.6% |
| Debt To Equity | 0.04x▼ | 0.11x |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹107 Cr +19.0% | ₹90 Cr -9.5% | ₹99 Cr +85.4% | ₹54 Cr |
| Other Income | ₹2 Cr +27.4% | ₹2 Cr +6.1% | ₹2 Cr +226.9% | ₹0.54 Cr |
| Total Income | ₹109 Cr +19.2% | ₹92 Cr -9.3% | ₹101 Cr +86.8% | ₹54 Cr |
| COGS | ₹19 Cr +13.0% | ₹17 Cr -34.8% | ₹26 Cr +76.6% | ₹15 Cr |
| ₹98 Cr +22.2% | ₹81 Cr -17.9% | ₹98 Cr +91.0% | ₹51 Cr | |
| Profit Before Tax | ₹11 Cr +9.2% | ₹10 Cr +245.6% | ₹3 Cr +5.9% | ₹3 Cr |
| Exceptional Items | ₹0.00 Cr +100.0% | (₹1 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹2 Cr -33.8% | ₹3 Cr +214.0% | ₹0.87 Cr +43.8% | ₹0.61 Cr | |
| Net Profit | ₹9 Cr +25.3% | ₹7 Cr +262.3% | ₹2 Cr -5.6% | ₹2 Cr |
| Profit (Owners) | ₹9 Cr +25.3% | ₹7 Cr ↑ Recovery | (₹0.01 Cr) ↓ Decline | ₹2 Cr |
| Minority Interest | (₹0.00 Cr) ↓ Decline | ₹0.00 Cr ↑ Recovery | (₹0.00 Cr) -100.0% | (₹0.00 Cr) |
| EPS | ₹8.55 | ₹6.82 | (₹0.01) | ₹1.99 |
| Diluted Shares | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Profit Or Loss Of Associates | (₹0.00 Cr) ↓ Decline | ₹0.02 Cr ↑ Recovery | (₹0.01 Cr) | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on July 24, 2026.
The Exchange had sought clarification from Vaidya Sane Ayurved Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requ...
Vaidya Sane Ayurved Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
The Exchange has sought clarification from Vaidya Sane Ayurved Laboratories Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requ...
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about Transcript
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about Audio recording of earnings conference
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
Vaidya Sane Ayurved Laboratories Limited has informed the Exchange about General Updates
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.